Jennifer Zhang

Jennifer Zhang

Auto-generated profile, based on publicly available information

Jennifer Zhang

Protein Analytical Chemistry, Genentech, A Member of the Roche Group, 1 DNA Way, South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in mAbs
Verified
Journal Article
Open access
BWBingchuan Wei
Bingchuan Wei
XGXuan Gao
Xuan Gao
LCLance Janssen Cadang
Lance Janssen Cadang
SISaeed Izadi
Saeed Izadi
PLPeilu Liu
Peilu Liu
GJGuoying Jiang
Guoying Jiang
Fc galactosylation is a critical quality attribute for anti-tumor recombinant immunoglobulin G (IgG)-based monoclonal antibody (mAb) therapeutics with complement-dependent cytotoxicity (CDC) as the mechanism of action. Although the correlation between galactosylation and CDC has been known, the underlying structure–function relationship is unclear. Heterogeneity of the Fc N-glycosylation produced by Chinese hamster ovary (CHO) cell culture biomanufacturing process leads to variable CDC potency. Here, we derived a kinetic model of galactose transfer reaction in the Golgi apparatus and used this model to determine the correlation between differently galactosylated species from CHO cell culture process. The model was validated by a retrospective data analysis of more than 800 historical samples from small-scale and large-scale CHO cell cultures. Furthermore, using various analytical technologies, we discovered the molecular basis for Fc glycan terminal galactosylation changing the three-dimensional conformation of the Fc, which facilitates the IgG1 hexamerization, thus enhancing C1q avidity and subsequent complement activation. Our study offers insight into the formation of galactosylated species, as well as a novel three-dimensional understanding of the structure–function relationship of terminal galactose to complement activation in mAb therapeutics.

2 May 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
JHJeffrey W. Hudgens
Jeffrey W. Hudgens
EGElyssia S. Gallagher
Elyssia S. Gallagher
IKIoannis Karageorgos
Ioannis Karageorgos
KAKyle W. Anderson
Kyle W. Anderson
JFJames J. Filliben
James J. Filliben
SUSarah Urata
Sarah Urata

8 January 2025 in Analytical Chemistry
Verified
Journal Article
Closed access
QCQinjingwen Cao
Qinjingwen Cao
JGJohn Guan
John Guan
DLDelia Li
Delia Li
JZJennifer Zhang
Jennifer Zhang
RTRiley Togashi
Riley Togashi
FYFeng Yang
Feng Yang

26 July 2021 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
KTKiana Tajdaran
Kiana Tajdaran
KFKonstantin Feinberg
Konstantin Feinberg
SMSeyed Kaveh Mirmoeini
Seyed Kaveh Mirmoeini
JZJennifer Zhang
Jennifer Zhang
TGTessa Gordon
Tessa Gordon
GBGregory H Borschel
Gregory H Borschel
Purpose: The cornea is the window through which we see the world and is one of the most densely innervated structures in the body. Besides providing protective sensory input, corneal nerves have been postulated to stimulate limbal stem cells (LSCs), hence governing corneal epithelial maintenance and recovery. Loss of corneal innervation, through injury, diabetes, tumors, infections, and even improper contact lens use, leads to neurotrophic keratopathy (NK), a degenerative corneal disease that is characterized by corneal epithelial breakdown, scarring, and permanent vision loss1. The only non-invasive treatment option for NK is the human recombinant nerve growth factor (rhNGF), but the short half-life of exogenous neurotrophins-based therapies make this therapeutic approach less effective2. Development of the small molecule ligands for neurotrophins receptors that have better pharmacokinetics and plasma stability showed promising results in the treatment of several neurodegenerative conditions in the recent years3. In this study, we were prompted to investigate the molecular mechanism of NK and the role of NGF receptors, TrkA and p75NTR, in corneal healing. We hypothesized that TrkA inhibition would delay corneal wound healing and p75NTR inhibition accelerates corneal healing. This knowledge will lay the basis for a new non-invasive approach for NK. Methods: For this experiment, we took advantage of commercially available Ntrk1 mutant mice, which allow for pharmacological inhibition of TrkA receptor with an inhibitor known as not mammalian kinase inhibitor (1-NM-PP1)4. Ntrk1 mice (n=20) were divided into three groups, which received saline injection as a control. In one experimental group animals were received TrkA inhibitor and the other group received both TrkA and p75 inhibitor for 5 days. On day six we removed the corneal epithelium with a 0.5 mm rotating brush. To measure epithelial healing, we performed digital imaging of fluorescein staining daily for four days after injury. We then harvested the corneas for immunofluorescent and biochemical analyses. Results: Our results show a significant delay in corneal epithelial healing following TrkA inhibition and acceleration in corneal healing after p75NTR inhibition. Conclusion: A selective TrkA agonist or p75NTR inhibitors could be a new therapeutic approach for NK.

5 January 2022 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
SDSimeon Christian Daeschler
Simeon Christian Daeschler
KFKonstantin Feinberg
Konstantin Feinberg
KMKaveh Mirmoeini
Kaveh Mirmoeini
KCKatelyn Chan
Katelyn Chan
JZJennifer Zhang
Jennifer Zhang
GBGregory H Borschel
Gregory H Borschel